Solly Chedid, MD, presents a patient case and provides clinical insights on approaching first-line therapy selection in patients with LR-MDS and moderate to severe anemia.
Frontline Use of Erythroid Maturating Agent (EMA): Luspatercept
A hematologist-oncologist discusses the efficacy and safety findings from the COMMANDS trial and how they inform treatment selection.
Solly Chedid, MD, provides clinical insights on quality-of-life assessment practices for patients with MDS.
An expert on myelodysplastic syndromes reviews recent real-world data presented at EHA 2024 showing the clinical benefit of luspatercept dose titration.
Solly Chedid, MD, shares insights on optimizing anemia management in patients with lower-risk MDS and outlines remaining unmet needs in treating anemia.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Insurance Delays and Travel Strain CAR T Referral in Early Relapsed Myeloma
2
NCCN Guidelines Add Cosibelimab for Locally Advanced CSCC
3
Real-World Data for Darolutamide vs Abiraterone Triplet Therapy in mHSPC
4
Oncologists Debate Role of On-Body Injector for Transplant-Ineligible Myeloma
5